the aid library

LIST OPTIONS

Filter

7955

Linking Disaster Risk Reduction (DRR) and Mental Health and Psychosocial Support (MHPSS) - Practical tools, approaches and case studies

World Health Organization (WHO) and InterAgency Standing Committee (IASC), Save the Children, et al. (2021) C_WHO

Technical Note Recently, the approach to hazardous events has undergone a considerable shift, away from reactive activities focused on managing and responding to events and towards a more proactive process of emergency and disaster risk management (DRM). The ultimate goal of this shift in focus is ... more

Situational assessment checklist to guide implementation of the global strategy for tuberculosis research and innovation

World Health Organization WHO (2021) C_WHO

Serious Illnesses in Infants and Children; Including Adolescent Girls Who Are Pregnant

Maternal & Childhealth Advocacy International MCAI (2021) C1

Handbook 2

WHO technical consultation on oxygen access scale-up for COVID-19

World Health Organization WHO (2021) C_WHO

Quality health services and palliative care: practical approaches and resources to support policy, strategy and practice

World Health Organisation (WHO) (2021) C_WHO

As countries commit to achieving universal health coverage, it is imperative to ensure that the design and delivery of palliative care services place attention on quality of care, with action needed across all domains of quality health services: effectiveness, safety, people-centredness, timeliness,... more

External Link

ERC Guidelines

European Resuscitation Council ERC (2021) CC

The European Resuscitation Council Guidelines for Resuscitation provide specific instructions for how resuscitation should be practiced and take into account ease of teaching and learning, as well as the science. They were developed by Europeans and have been specifically written with European pract... more

Download (253)

View PDF (286)

WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia

World Health Organization WHO (2021) C_WHO

External Link

WHO Global Atlas of Traditional, Complementary and Alternative Medicines. Text and map volume

Bodeker, Gerard, Ong, Chi-Keong, Grundy, Chris, Burford, Gemma, Shein, Kin. et al. (‎2005)‎. WHO global atlas of traditional, complementary and alternative medicine. Kobe, Japa World Health Organization WHO (2005) C_WHO

Download (192)

View PDF (236)

Setting Up a Cancer Centre: A WHO–IAEA Framework

World Health Organization WHO; International Atomic Energy Agency IAEA (1989) C1

Cancer centres are a major resource in ensuring a comprehensive approach to cancer treatment and its planning. As part of a new roadmap developed by WHO and IAEA to help countries design national cancer control programmes, this publication proposes a framework to develop a cancer centre and/or to st... more

Guideline for Preventive Chemotherapy for the Control of Taenia solium Taeniasis

Pan American Health Organisation PAHO (2021) C_WHO

The larval stage of the parasite Taenia solium can encyst in the central nervous system causing neurocysticercosis, which is the main cause of acquired epilepsy in the countries in which the parasite is endemic. Endemic areas are those with the presence (or likely presence) of the full life cycle of... more

India: health system review

Srivastava, Swati, Karan, Anup K., Bhan, Nandita, Mukhopadhya, Indranil. et al. .World Health Organization (WHO), Regional Office for South-East Asia (2022) C_WHO

Integration of mental health and HIV interventions

World Health Organization WHO, UNICEF (2022) C_WHO

This joint publication by UNAIDS and WHO emphasizes the importance of integrating HIV prevention, testing, treatment and care and mental health services for people living with HIV. It provides a compilation of tools, best practices, recommendations and guidelines that facilitate the integration of i... more

Download (144)

View PDF (346)

Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031

World Health Organization WHO (2022) C_WHO

Draft plan

Download (146)

View PDF (326)

Third progress analysis of implementation of antimicrobial resistance national action plans in the WHO South-East Asia Region

World Health Organization WHO (2022) C_WHO

Antimicrobial resistance (AMR) is described as a situation when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder or impossible to treat, and increasing the risk of disease spread, severe illness and death.1 AMR in recent years has... more

External Link

Lignes directrices provisoires de l’OMS pour le traitement de la trypanosomiase humaine africaine à T. b. gambiense

World Health Organization WHO (2019) C_WHO

Les progrès remarquables réalisés dans la lutte contre la forme à T. b. gambiense reposent sur le dépistage et le traitement curatif, une stratégie qui interrompt la transmission en réduisant le réservoir de parasites chez l’être humain. Parfois, cette approche a été combinée avec des... more

External Link

Eradication of yaws: a guide for programme managers, a disfiguring non-venereal disease

World Health Organization WHO (2018) C_WHO

Yaws is a disfiguring non-venereal disease caused by infection with the spirochaete. Treponema pallidum subspecies pertenue which is closely related to the causative agent of syphilis and those of the other endemic treponematoses, bejel and pinta. The disease is endemic in certain areas of the World... more

Accelerating anaemia reduction: a comprehensive framework for action

World Health Organisation (WHO) (2023) C_WHO

This document is an output of a WHO cross-programme initiative aiming to improve the prevention, diagnosis and management of anaemia and thereby accelerate reduction in its prevalence. It comes at an important time, midway through the era of the Sustainable Development Goals, when progress in reduci... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Policy Snapshot: Cholesterol Control and Management in Brazil

World Heart Federation (2015) CC

Worldwide, there are about 17 million deaths due to cardiovascular disease (CVD) each year and at least two or three times as many non-fatal events. Raised cholesterol greatly increases the risks of stroke and heart disease, causing a large health burden across the world. The World Health Organizat... more

Burden of fungal asthma in Africa: A systematic review and meta-analysis

Kwizera, R.; Musaazi, J.; Meya, D.B.; et al. PLOS ONE, which is part of the Public Library of Science (PLOS) (2019) CC2

Asthma is one of the neglected diseases in Africa with a high prevalence. Allergic fungal diseases have been reported to complicate asthma progression and treatment outcomes. However, data about fungal asthma and its associated complications are limited in Africa. We aimed to estimate the burden of ... more